5.71
Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten
What drives Monte Rosa Therapeutics Inc. stock priceFree Trend-Following Techniques - Autocar Professional
Is Monte Rosa Therapeutics Inc. a good long term investmentFree Trading Strategy Suggestions - Autocar Professional
Monte Rosa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
What analysts say about Monte Rosa Therapeutics Inc. stockExplosive returns - jammulinksnews.com
Monte Rosa Therapeutics Announces First Subjects Dosed in - GlobeNewswire
Monte Rosa Therapeutics and the Breakthrough Potential of MRT-8102 in Inflammatory Disease Treatment - AInvest
Monte Rosa begins phase 1 trial of NEK7-targeting molecular glue degrader - Investing.com
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases - GlobeNewswire
First-Ever NEK7 Degrader Enters Clinical Trials: Monte Rosa's Novel Approach Targets Multiple Inflammatory Diseases - Stock Titan
Monte Rosa (GLUE) Soars 13.58% in Three Days, Hits 2025 High - AInvest
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Monte Rosa Therapeutics Inc (GLUE) Stock: A Year of Market Movement, Down and Up - investchronicle.com
How Monte Rosa Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - beatles.ru
What makes Monte Rosa Therapeutics Inc. stock price move sharplyFree Consultation - Newser
Why Monte Rosa Therapeutics Inc. stock attracts strong analyst attention2x 3x 5x Pick Alert - Newser
With surface mimicry, molecular glues shed hairpin need - BioWorld MedTech
Monte Rosa Therapeutics (GLUE) Soars 4.55% on Clinical Trial Progress - AInvest
Monte Rosa Therapeutics (GLUE): Pioneering the Future of Drug Discovery with Molecular Glue Degraders - AInvest
Monte Rosa Therapeutics Announces Publication of Landmark Research on Molecular Glue Degraders in Science - Nasdaq
Monte Rosa Announces Publication in Science of Key Insights - GlobeNewswire
Monte Rosa Announces Publication in Science of Key Insights That Enable Next Generation Molecular Glue Degrader Medicines - MarketScreener
Monte Rosa's AI Discovery Unlocks 100+ New Drug Targets, Featured in Science Magazine Cover Story - Stock Titan
Monte Rosa gets FDA clearance to begin testing MRT-8102 - MSN
FMR LLC Reduces Stake in Monte Rosa Therapeutics Inc. - GuruFocus
Bank of America Corp DE Reduces Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Monte Rosa’s molecular glue degrader MRT-8102 gains IND clearance for inflammatory conditions - BioWorld MedTech
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):